Director/PDMR Shareholding

Vectura Group plc

NOTIFICATION OF DIRECTORS/PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

Chippenham, UK, 20 June 2016: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that on 17 June 2016, Andrew Derodra, Chief Financial Officer, exercised nil-cost options over 150,000 £1 ordinary shares in Skyepharma PLC ("Skyepharma") arising from the Skyepharma Long Term Incentive Plan which vested on completion of the merger of Skyepharma and Vectura. These shares were automatically converted into New Vectura Shares under the terms of the Scheme of Arrangement dated 8 April 2016 by which ordinary shares in Skyepharma are exchanged for ordinary shares of 0.025 pence in Vectura at a ratio of 2.7977405 Vectura shares for each Skyepharma share.

Accordingly, on 17 June 2016 Andrew Derodra became the beneficial owner of 419,661 Vectura shares which were all disposed later that day in London at an average price of £1.536209 per share.

Following the above exercise of options, Andrew Derodra retains 123,052 vested options over shares in Skyepharma which lapse if not otherwise exercised, on 8 July 2016.

The total interest in shares of the Company held by Andrew Derodra remains at 222,243.

Vectura Group plc was notified of the above transactions on 17 June 2016.

Enquiries:

John Murphy, Company Secretary + 44 (0)207 881 0524